PTC Therapeutics Inc. diskutieren
PTC Therapeutics Inc.
WKN: A1W0MW / Symbol: PTCT / Name: PTC Therapeutics / Aktie / Biotechnologie & medizinische Forschung / Mid Cap /
60,26 €
-0,40 %
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at UBS Group AG from $71.00 to $80.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Cantor Fitzgerald from $112.00 to $120.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Wells Fargo & Company from $74.00 to $78.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Bank of America Corporation from $68.00 to $84.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Truist Financial Corporation from $80.00 to $86.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its "outperform" rating re-affirmed by analysts at Royal Bank Of Canada.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics, Inc. (NASDAQ: PTCT) had its price target raised by analysts at Wells Fargo & Company from $78.00 to $79.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Bank of America Corporation from $82.00 to $76.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Morgan Stanley from $76.00 to $71.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Wells Fargo & Company from $79.00 to $73.00. They now have an "overweight" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $118.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) is now covered by analysts at Wells Fargo & Company. They set an "overweight" rating and a $73.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "buy" rating reaffirmed by analysts at Jefferies Financial Group Inc..
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "sell" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target raised by analysts at Royal Bank Of Canada from $70.00 to $82.00. They now have an "outperform" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its price target lowered by analysts at Bank of America Corporation from $97.00 to $93.00. They now have a "buy" rating on the stock.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (NASDAQ:PTCT) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Ratings data for PTCT provided by MarketBeat
PTC Therapeutics (PTCT) is now covered by Raymond James Financial, Inc.. They set an "outperform" rating and a $108.00 price target on the stock.
Ratings data for PTCT provided by MarketBeat
Neueste Beiträge
BNP_Paribas_Exane in Microsoft Corp. diskutieren